IFNG and infection: While the Phase IIb trial of M72/AS01E only enrolled adults with a positive interferon-gamma release assay (IGRA) value, previous trials have indicated that an immune response is invoked in adolescents both with and without infection, and the phase III trial will enrol IGRA positive and negative individuals aged 15–44 years.